493 related articles for article (PubMed ID: 31195178)
1. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
2. Target engagement imaging of PARP inhibitors in small-cell lung cancer.
Carney B; Kossatz S; Lok BH; Schneeberger V; Gangangari KK; Pillarsetty NVK; Weber WA; Rudin CM; Poirier JT; Reiner T
Nat Commun; 2018 Jan; 9(1):176. PubMed ID: 29330466
[TBL] [Abstract][Full Text] [Related]
3. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
4. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts.
Laird JH; Lok BH; Ma J; Bell A; de Stanchina E; Poirier JT; Rudin CM
Clin Cancer Res; 2018 Oct; 24(20):5143-5152. PubMed ID: 29945991
[No Abstract] [Full Text] [Related]
5. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
6. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Lok BH; Gardner EE; Schneeberger VE; Ni A; Desmeules P; Rekhtman N; de Stanchina E; Teicher BA; Riaz N; Powell SN; Poirier JT; Rudin CM
Clin Cancer Res; 2017 Jan; 23(2):523-535. PubMed ID: 27440269
[TBL] [Abstract][Full Text] [Related]
7. Talazoparib Dual-targeting on Poly (ADP-ribose) Polymerase-1 and -16 Enzymes Offers a Promising Therapeutic Strategy in Small Cell Lung Cancer Therapy: Insight from Biophysical Computations.
Mgoboza C; Okunlola FO; Akawa OB; Aljoundi A; Soliman MES
Cell Biochem Biophys; 2022 Sep; 80(3):495-504. PubMed ID: 35588345
[TBL] [Abstract][Full Text] [Related]
8. DoE Optimization Empowers the Automated Preparation of Enantiomerically Pure [
Bowden GD; Stotz S; Kinzler J; Geibel C; Lämmerhofer M; Pichler BJ; Maurer A
J Med Chem; 2021 Nov; 64(21):15690-15701. PubMed ID: 34672571
[TBL] [Abstract][Full Text] [Related]
9. Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[
Demétrio de Souza França P; Roberts S; Kossatz S; Guru N; Mason C; Zanoni DK; Abrahão M; Schöder H; Ganly I; Patel SG; Reiner T
Nucl Med Biol; 2020; 84-85():80-87. PubMed ID: 32135475
[TBL] [Abstract][Full Text] [Related]
10. An
Zmuda F; Blair A; Liuzzi MC; Malviya G; Chalmers AJ; Lewis D; Sutherland A; Pimlott SL
J Med Chem; 2018 May; 61(9):4103-4114. PubMed ID: 29630818
[TBL] [Abstract][Full Text] [Related]
11. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
12. Design, Synthesis, and Evaluation of [
Zheng W; Huang Y; Xie Y; Yang T; Cheng X; Chen H; Li C; Jiang Z; Yu Z; Li Z; Zhang L; Yuan L; Liu Y; Liang Y; Wu Z
Mol Pharm; 2024 May; 21(5):2606-2621. PubMed ID: 38606716
[TBL] [Abstract][Full Text] [Related]
13. Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition.
Pai Bellare G; Saha B; Patro BS
Br J Cancer; 2021 Mar; 124(7):1260-1274. PubMed ID: 33473172
[TBL] [Abstract][Full Text] [Related]
14. BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells.
Fiorentino FP; Marchesi I; Schröder C; Schmidt R; Yokota J; Bagella L
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33339368
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux.
Pai Bellare G; Sankar Patro B
Biochem Pharmacol; 2022 May; 199():115024. PubMed ID: 35367197
[TBL] [Abstract][Full Text] [Related]
17. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Cardnell RJ; Feng Y; Diao L; Fan YH; Masrorpour F; Wang J; Shen Y; Mills GB; Minna JD; Heymach JV; Byers LA
Clin Cancer Res; 2013 Nov; 19(22):6322-8. PubMed ID: 24077350
[TBL] [Abstract][Full Text] [Related]
18. [
Shuhendler AJ; Cui L; Chen Z; Shen B; Chen M; James ML; Witney TH; Bazalova-Carter M; Gambhir SS; Chin FT; Graves EE; Rao J
Bioconjug Chem; 2019 May; 30(5):1331-1342. PubMed ID: 30973715
[TBL] [Abstract][Full Text] [Related]
19. Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.
Kizilbash SH; Gupta SK; Chang K; Kawashima R; Parrish KE; Carlson BL; Bakken KK; Mladek AC; Schroeder MA; Decker PA; Kitange GJ; Shen Y; Feng Y; Protter AA; Elmquist WF; Sarkaria JN
Mol Cancer Ther; 2017 Dec; 16(12):2735-2746. PubMed ID: 28947502
[TBL] [Abstract][Full Text] [Related]
20. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
Xiong J; Barayan R; Louie AV; Lok BH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
